# A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC

> **NCT05896059** · PHASE2 · UNKNOWN · sponsor: **Zhejiang Cancer Hospital** · enrollment: 21 (estimated)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT05896059
- **Lead sponsor:** Zhejiang Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-15
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2023-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896059, "A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05896059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*